Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
This paragraph explains the components included in the index level and what phenomena it aggregates. It offers a concise overview to anchor deeper study.
13,672 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
XRP trades near $1.50 as XRPL tokenization accelerates. Analysts weigh whether the token could reach $10 if XRP becom...
Celcuity stock popped today after the company released its 2025 results, showing a tighter quarterly loss despite no ...
Washington moves to outlaw noncompete agreements statewide, imposing a 2027 deadline. The sweeping policy reshapes hi...
Bitcoin harbors a tense battlefield near the $80,000 zone as aging coins hit the market and institutional buyers abso...
Investors eyeing DEI in 2026 should study the Q1 results, leverage, and lease metrics that shape the office REIT's tr...
A Federal Reserve study shows the price surge hitting low-income households hardest, revealing a widening gap in ener...
A pivotal week looms as the Federal Reserve eyes its next move. This guide breaks down what a policy shift could mean...
Bitcoin surged above $80,000 as ceasefire headlines circulated, signaling renewed risk appetite in crypto markets. Th...
In volatile markets, some investors look to physical metals for ballast. This article breaks down why ishares silver ...
Tron’s TRX surged in 2026, yet fresh on-chain data points to a potential correction risk as price outpaces network ac...
Andreessen Horowitz is tapping California’s pension funds for the first time, led by CalPERS’ $400 million commitment...